The activities of the second edition of the United States Pharmacopeia (USP) Convention, which was held in Egypt under the auspices and participation of the Egyptian Drug Authority, have concluded.

The conference activities began with a speech by Dr. Ali Al-Ghamrawi, Chairman of the Egyptian Drug Authority, which he delivered virtually via video conference. The conference was also attended by Dr. Aiman Al-Khatib, Vice President of The Egyptian Drug Authority, and Dr. Rasha Ziyadah, Egyptian Drug Authority Chairman's Assistant for Technical Development and Capability Building Affairs, in addition to a number of heads of central departments of the Egyptian Drug Authority, and Mr. Dr. Jamal Al-Lithy, Chairman of the Chamber of Pharmaceutical Industries, as well as representatives of global and local pharmaceutical companies, experts, and representatives of scientific research and the pharmaceutical industry.

In his speech, the Chairman of the Egyptian Drug Authority affirmed his welcome to the partnership between the Egyptian Drug Authority and the United States Pharmacopeia, which reflects the Egyptian Drug Authority's commitment to applying the latest optimal standards and criteria for drug control; to ensure that patients receive safe and effective drugs.

For his part, Dr. Aiman Al-Khatib, Vice President of The Egyptian Drug Authority, confirmed that the Egyptian Drug Authority is taking confident steps towards formulating the Egyptian Pharmacopoeia, and that it is cooperating with the United States Pharmacopeia in this regard, in order to benefit from the expertise and scientific references, and to formulate the Egyptian Pharmacopoeia according to the latest scientific and technological developments that enable the establishment of clear and accredited reference frameworks and controls for everything related to the pharmaceutical system.

The conference included a number of training workshops and discussion sessions, which focused on the most important topics related to drug, raw material, and post-marketing surveillance.

This comes within the framework of the Egyptian Drug Authority 's continuous efforts and its constant keenness to coordinate and consult with various international bodies; to keep pace with and apply international standards in drug control, develop long-term strategic plans, and exchange technical expertise; which has a positive impact on the performance of the Egyptian regulatory and industrial system."